Ovarian Cancer-Associated Ascites Have High Proportions of Cytokine-Responsive CD56bright NK Cells.
Adult
Aged
Aged, 80 and over
Apyrase
/ genetics
Ascites
/ genetics
CD56 Antigen
/ genetics
Cystadenocarcinoma, Serous
/ genetics
Female
Gene Expression Regulation, Neoplastic
Humans
Immunophenotyping
Interleukin-10
/ genetics
Interleukin-15
/ genetics
Interleukin-2
/ genetics
Interleukin-6
/ genetics
K562 Cells
Killer Cells, Natural
/ immunology
Middle Aged
Neoplasm Grading
Neoplasm Staging
Ovarian Neoplasms
/ genetics
Programmed Cell Death 1 Receptor
/ genetics
STAT5 Transcription Factor
/ genetics
Signal Transduction
T-Lymphocytes
/ immunology
Tumor Microenvironment
/ genetics
STAT5
cytotoxic lymphocytes
ectonucleotidases
inhibitory checkpoint receptor
pS6
tumor microenvironment
Journal
Cells
ISSN: 2073-4409
Titre abrégé: Cells
Pays: Switzerland
ID NLM: 101600052
Informations de publication
Date de publication:
06 07 2021
06 07 2021
Historique:
received:
24
04
2021
revised:
21
06
2021
accepted:
22
06
2021
entrez:
7
8
2021
pubmed:
8
8
2021
medline:
29
10
2021
Statut:
epublish
Résumé
Ovarian cancer is the most lethal gynecological malignancy, with serous histotype as the most prevalent epithelial ovarian cancer (EOC). Peritoneal ascites is a frequent comorbidity in advanced EOC. EOC-associated ascites provide a reliable sampling source for studying lymphocytes directly from tumor environment. Herein, we carried out flow cytometry-based analysis to readdress issues on NK and T lymphocyte subsets in women with advanced EOC, additionally evaluating phenotypic modulation of their intracellular pathways involved in interleukin (IL)-2 and IL-15 signaling. Results depicted ascites as an inflammatory and immunosuppressive environment, presenting significantly (
Identifiants
pubmed: 34359872
pii: cells10071702
doi: 10.3390/cells10071702
pmc: PMC8306021
pii:
doi:
Substances chimiques
CD56 Antigen
0
IL10 protein, human
0
IL15 protein, human
0
IL6 protein, human
0
Interleukin-15
0
Interleukin-2
0
Interleukin-6
0
NCAM1 protein, human
0
PDCD1 protein, human
0
Programmed Cell Death 1 Receptor
0
STAT5 Transcription Factor
0
Interleukin-10
130068-27-8
Apyrase
EC 3.6.1.5
ENTPD1 protein, human
EC 3.6.1.5
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : Coordenação de Aperfeiçoamento de Pessoal de Nível Superior
ID : Claudia R Tonetti's scholarship
Organisme : Fundação de Amparo à Pesquisa do Estado de São Paulo
ID : 2018/06959-1, 2018/18047-7, 2019/25113-9 and 2020/11628-4
Références
J Exp Med. 2005 Oct 17;202(8):1075-85
pubmed: 16230475
Front Immunol. 2020 Feb 11;11:7
pubmed: 32117218
Am J Surg Pathol. 2016 Sep;40(9):1165-76
pubmed: 27487741
Ann Oncol. 2007 May;18(5):945-9
pubmed: 17298959
Leukemia. 2003 Oct;17(10):1973-80
pubmed: 14513047
Clin Cancer Res. 2013 Mar 15;19(6):1363-74
pubmed: 23340297
Arch Gynecol Obstet. 2019 Feb;299(2):515-523
pubmed: 30415435
Oncotarget. 2015 May 30;6(15):13835-43
pubmed: 26079948
Clin Cancer Res. 2008 Aug 15;14(16):5198-208
pubmed: 18698038
Cancer Discov. 2014 Aug;4(8):879-88
pubmed: 25035124
Lancet. 2000 Nov 25;356(9244):1795-9
pubmed: 11117911
J Immunol Res. 2015;2015:191832
pubmed: 26236750
J Immunol. 2013 Apr 15;190(8):3939-48
pubmed: 23487420
Hum Immunol. 2001 Oct;62(10):1092-8
pubmed: 11600215
Neoplasia. 2013 Feb;15(2):133-42
pubmed: 23441128
Nature. 2011 Jun 29;474(7353):609-15
pubmed: 21720365
Oncotarget. 2016 Feb 9;7(6):7318-28
pubmed: 26802025
J Clin Invest. 2017 Nov 1;127(11):4042-4058
pubmed: 28972539
Immunol Lett. 2016 Oct;178:15-9
pubmed: 27185471
BMC Cancer. 2017 Nov 13;17(1):756
pubmed: 29132324
Cancer Res. 2012 Nov 15;72(22):5721-32
pubmed: 22986739
Cancer Discov. 2016 Apr;6(4):414-29
pubmed: 26873347
Int J Cancer. 2021 Apr 5;:
pubmed: 33818764
Gynecol Oncol. 2010 May;117(2):366-72
pubmed: 20144842
Nat Commun. 2014 Aug 14;5:4539
pubmed: 25119382
Semin Immunol. 2017 Jun;31:20-29
pubmed: 28888619
Cancer Metastasis Rev. 2015 Mar;34(1):53-74
pubmed: 25544369
Biofactors. 2010 Jul-Aug;36(4):274-88
pubmed: 20623510
Immunology. 2007 Nov;122(3):418-29
pubmed: 17617155
Cancer Immunol Res. 2017 Oct;5(10):929-938
pubmed: 28842470
Front Immunol. 2021 Mar 18;12:610789
pubmed: 33815365
Cancer Res. 2021 Jan 1;81(1):158-173
pubmed: 33158814
Hum Immunol. 2014 Aug;75(8):777-84
pubmed: 24882570
Oncoimmunology. 2015 Jan 22;4(4):e1001224
pubmed: 26137398
Oncotarget. 2016 Nov 8;7(45):72961-72977
pubmed: 27662664
Immunol Cell Biol. 2014 Mar;92(3):210-3
pubmed: 24492800
Gynecol Oncol. 2007 Jul;106(1):75-81
pubmed: 17433425
Immunobiology. 2017 Jan;222(1):11-20
pubmed: 26264743
Br J Cancer. 2020 Jul;123(1):9-16
pubmed: 32382112
Methods Mol Biol. 2010;612:335-52
pubmed: 20033652
Contemp Oncol (Pozn). 2015;19(4):290-9
pubmed: 26557777
Cancer Immunol Immunother. 2011 Oct;60(10):1405-18
pubmed: 21638125
Blood. 2003 Apr 15;101(8):3052-7
pubmed: 12480696
Trends Immunol. 2001 Nov;22(11):633-40
pubmed: 11698225
Neoplasma. 2013;60(5):546-52
pubmed: 23790174
Scand J Immunol. 2011 Sep;74(3):244-252
pubmed: 21595734
Cancer Res. 2007 Jan 15;67(2):585-92
pubmed: 17234767
Discov Med. 2016 Mar;21(115):197-203
pubmed: 27115170
Am J Pathol. 2016 Apr;186(4):733-47
pubmed: 27012190
Clin Immunol. 2017 Apr;177:50-59
pubmed: 26476139
Clin Cancer Res. 2006 Oct 1;12(19):5850-8
pubmed: 17020993
Sci Rep. 2021 Feb 18;11(1):4130
pubmed: 33602987
Mol Cancer. 2014 May 29;13:129
pubmed: 24886523
Cancer Res. 2012 Jun 1;72(11):2701-4
pubmed: 22593197
J Immunol. 2004 Feb 1;172(3):1455-62
pubmed: 14734722
Am J Surg Pathol. 2016 May;40(5):627-35
pubmed: 26900814
Int J Mol Sci. 2017 May 17;18(5):
pubmed: 28513532
Clin Transl Immunology. 2021 Jan 10;10(1):e1238
pubmed: 33456775
Front Oncol. 2013 Sep 25;3:256
pubmed: 24093089
Sci Signal. 2016 Feb 16;9(415):ra19
pubmed: 26884601
CA Cancer J Clin. 2018 Nov;68(6):394-424
pubmed: 30207593
Nat Med. 2006 Sep;12(9):1065-74
pubmed: 16892062
Cancer Immunol Immunother. 2015 Mar;64(3):337-47
pubmed: 25416072
Exp Hematol. 2011 Sep;39(9):904-14
pubmed: 21703984
Am J Cancer Res. 2016 Oct 01;6(10):2235-2251
pubmed: 27822414
Nature. 2015 Jan 15;517(7534):293-301
pubmed: 25592534
J Immunol. 2006 Feb 1;176(3):1582-7
pubmed: 16424187
J Immunol. 2009 Oct 15;183(8):4921-30
pubmed: 19801517
Nat Rev Cancer. 2005 May;5(5):355-66
pubmed: 15864277
J Immunol. 2016 Apr 1;196(7):2923-31
pubmed: 26994304